STAND. COM. REP. NO. 953

                                 Honolulu, Hawaii
                                                   , 1999

                                 RE: H.B. No. 848
                                     H.D. 2




Honorable Calvin K.Y. Say
Speaker, House of Representatives
Twentieth State Legislature
Regular Session of 1999
State of Hawaii

Sir:

     Your Committee on Judiciary and Hawaiian Affairs, to which
was referred H.B. No. 848, H.D. 1, entitled: 

     "A BILL FOR AN ACT RELATING TO SUBSTANCE ABUSE TESTING,"

begs leave to report as follows:

     The purpose of this bill is to permit employers to use
substance abuse on-site screening tests that meet the commercial
distribution guideline requirements of the United States Food and
Drug Administrations (FDA) for pre-employment screening purposes
only.

     Your Committee received testimony in support of this bill
from the Department of Health and Hoffman LaRoche
Pharmaceuticals.

     Your Committee finds that the use of approved methods for
on-site substance abuse screening tests would bring uniformity
and conformity with set standards.

     Your Committee amended this bill by exempting substance
abuse on-site testing from Chapter 329B of the Hawaii Revised
Statutes, based on the fact that the on-site testing device to be
used must meet the strict requirement of the FDA.

     As affirmed by the record of votes of the members of your
Committee on Judiciary and Hawaiian Affairs that is attached to
this report, your Committee is in accord with the intent and
purpose of H.B. No. 848, H.D. 1, as amended herein, and

 
 
                                 STAND. COM. REP. NO. 953
                                 Page 2

 
recommends that it pass Third Reading in the form attached hereto
as H.B. No. 848, H.D. 2.

                                   Respectfully submitted on
                                   behalf of the members of the
                                   Committee on Judiciary &
                                   Hawaiian Affairs,



                                   ______________________________
                                   PAUL T. OSHIRO, Chair